Family · Pharmaceutical analytical standards
Sibutramine
A serotonin and noradrenaline reuptake inhibitor that reduces appetite. Developed in Nottingham, England, in 1988 and approved in the United States in 1997 to treat obesity alongside a diet, it was withdrawn from most markets in 2010. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?It began life as a potential antidepressant: during development the research was redirected towards appetite control, and the molecule became a weight-loss medicine.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
